Viruses,
Journal Year:
2023,
Volume and Issue:
15(3), P. 668 - 668
Published: March 2, 2023
Compared
to
other
vaccines,
the
inherent
properties
of
messenger
RNA
(mRNA)
vaccines
and
their
interaction
with
lipid
nanoparticles
make
them
considerably
unstable
throughout
life
cycles,
impacting
effectiveness
global
accessibility.
It
is
imperative
improve
mRNA
vaccine
stability
investigate
factors
influencing
stability.
Since
structure,
excipients,
nanoparticle
(LNP)
delivery
systems,
manufacturing
processes
are
primary
affecting
stability,
optimizing
structure
screening
excipients
can
effectively
Moreover,
improving
could
also
prepare
thermally
stable
safety
efficacy.
Here,
we
review
regulatory
guidance
associated
summarize
key
propose
a
possible
research
path
Signal Transduction and Targeted Therapy,
Journal Year:
2022,
Volume and Issue:
7(1)
Published: March 23, 2022
Abstract
To
date,
the
coronavirus
disease
2019
(COVID-19)
caused
by
severe
acute
respiratory
syndrome
2
(SARS-CoV-2)
has
determined
399,600,607
cases
and
5,757,562
deaths
worldwide.
COVID-19
is
a
serious
threat
to
human
health
globally.
The
World
Health
Organization
(WHO)
declared
pandemic
major
public
emergency.
Vaccination
most
effective
economical
intervention
for
controlling
spread
of
epidemics,
consequently
saving
lives
protecting
population.
Various
techniques
have
been
employed
in
development
vaccines.
Among
these,
messenger
RNA
(mRNA)
vaccine
drawing
increasing
attention
owing
its
great
application
prospects
advantages,
which
include
short
cycle,
easy
industrialization,
simple
production
process,
flexibility
respond
new
variants,
capacity
induce
better
immune
response.
This
review
summarizes
current
knowledge
on
structural
characteristics,
antigen
design
strategies,
delivery
systems,
industrialization
potential,
quality
control,
latest
clinical
trials
real-world
data
mRNA
vaccines
as
well
technology.
Current
challenges
future
directions
preventive
infectious
diseases
are
also
discussed.
Cell Death and Disease,
Journal Year:
2022,
Volume and Issue:
13(7)
Published: July 23, 2022
Abstract
The
growing
understanding
of
RNA
functions
and
their
crucial
roles
in
diseases
promotes
the
application
various
RNAs
to
selectively
function
on
hitherto
“undruggable”
proteins,
transcripts
genes,
thus
potentially
broadening
therapeutic
targets.
Several
RNA-based
medications
have
been
approved
for
clinical
use,
while
others
are
still
under
investigation
or
preclinical
trials.
Various
techniques
explored
promote
intracellular
trafficking
metabolic
stability,
despite
significant
challenges
developing
therapeutics.
In
this
review,
mechanisms
action,
challenges,
solutions,
therapeutics
comprehensively
summarized.
Molecular Therapy,
Journal Year:
2022,
Volume and Issue:
30(5), P. 1850 - 1868
Published: Feb. 19, 2022
Since
the
first
successful
application
of
messenger
ribonucleic
acid
(mRNA)
as
a
vaccine
agent
in
preclinical
study
nearly
30
years
ago,
numerous
advances
have
been
made
field
mRNA
therapeutic
technologies.
This
research
uncovered
unique
favorable
characteristics
vaccines,
including
their
ability
to
give
rise
non-toxic,
potent
immune
responses
and
potential
design
upscale
them
rapidly,
making
excellent
candidates
during
coronavirus
disease
2019
(COVID-19)
pandemic.
Indeed,
two
vaccines
against
COVID-19
receive
accelerated
regulatory
authorization
were
nucleoside-modified
which
showed
more
than
90%
protective
efficacy
symptomatic
severe
acute
respiratory
syndrome
2
(SARS-CoV-2)
infection
alongside
tolerable
safety
profiles
pivotal
phase
III
clinical
trials.
Real-world
evidence
following
deployment
global
vaccination
campaigns
utilizing
has
bolstered
trial
further
illustrated
that
this
technology
can
be
used
safely
effectively
combat
COVID-19.
unprecedented
success
also
emphasized
broader
new
drug
class,
not
only
for
other
infectious
diseases,
but
indications,
such
cancer
inherited
diseases.
review
presents
brief
history
current
status
development
four
platforms,
unmodified
mRNA,
circular
RNA,
self-amplifying
well
an
overview
recent
progress
vaccines.
We
discuss
anticipated
challenges
these
technologies,
may
important
future
endeavors
applications.
Advanced Materials,
Journal Year:
2023,
Volume and Issue:
35(51)
Published: May 17, 2023
Abstract
Messenger
RNA
(mRNA)
has
received
great
attention
in
the
prevention
and
treatment
of
various
diseases
due
to
success
coronavirus
disease
2019
(COVID‐19)
mRNA
vaccines
(Comirnaty
Spikevax).
To
meet
therapeutic
purpose,
it
is
required
that
must
enter
target
cells
express
sufficient
proteins.
Therefore,
development
effective
delivery
systems
necessary
crucial.
Lipid
nanoparticle
(LNP)
represents
a
remarkable
vehicle
indeed
accelerated
applications
humans,
as
several
mRNA‐based
therapies
have
already
been
approved
or
are
clinical
trials.
In
this
review,
focus
on
mRNA‐LNP‐mediated
anticancer
therapy.
It
summarizes
main
strategies
mRNA‐LNP
formulations,
discusses
representative
approaches
cancer,
points
out
current
challenges
possible
future
directions
research
field.
hoped
these
delivered
messages
can
help
further
improve
application
technology
cancer
Cell Research,
Journal Year:
2021,
Volume and Issue:
31(7), P. 732 - 741
Published: May 21, 2021
Abstract
SARS-CoV-2
variants
could
induce
immune
escape
by
mutations
on
the
receptor-binding
domain
(RBD)
and
N-terminal
(NTD).
Here
we
report
humoral
response
to
circulating
variants,
such
as
501Y.V2
(B.1.351),
of
plasma
neutralizing
antibodies
(NAbs)
elicited
CoronaVac
(inactivated
vaccine),
ZF2001
(RBD-subunit
vaccine)
natural
infection.
Among
86
potent
NAbs
identified
high-throughput
single-cell
VDJ
sequencing
peripheral
blood
mononuclear
cells
from
vaccinees
convalescents,
near
half
anti-RBD
showed
major
neutralization
reductions
against
K417N/E484K/N501Y
mutation
combination,
with
E484K
being
dominant
cause.
VH3-53/VH3-66
recurrent
respond
differently
RBD
K417N
compromises
majority
activity
through
reduced
polar
contacts
complementarity
determining
regions.
In
contrast,
242–244
deletion
(242–244Δ)
would
abolish
most
anti-NTD
interrupting
conformation
NTD
antigenic
supersite,
indicating
a
much
less
diversity
than
NAbs.
Plasma
convalescents
displayed
comparable
pseudo-
authentic
mainly
caused
E484K/N501Y
242–244Δ,
effects
additive.
Importantly,
RBD-subunit
exhibit
markedly
higher
tolerance
since
display
high
are
unaffected
mutations.
Moreover,
an
extended
gap
between
third
second
doses
leads
better
standard
three-dose
administration.
Together,
these
results
suggest
that
deployment
RBD-vaccines,
third-dose
boost,
may
be
ideal
for
combating
when
necessary,
especially
those
carrying
disrupt
supersite.
